Magnesium, Vitamins and Herbal Preparations

  • Alexander Mauskop
  • Christina Sun-Edelstein
Reference work entry


Headache patients frequently seek alternatives to traditional acute and preventative treatments, given the side effects often associated with conventional medications. In this chapter, the available evidence for the use of magnesium, coenzyme Q10 (CoQ10), riboflavin, butterbur, feverfew, and alpha lipoic acid in migraine prevention are reviewed. Areas of ongoing research, particularly in pharmacogenetics, are also discussed. Although further research with large-scale randomized controlled trials (RCTs) is necessary to better clarify the efficacy of these vitamins, supplements, and herbal preparations, we recommend the consideration of oral magnesium supplementation in migraineurs in whom there is clinical suspicion of magnesium deficiency, given its safety and tolerability. Butterbur is also recommended for migraine prophylaxis given the positive results from two randomized controlled trials. Though the clinical efficacy data for feverfew, CoQ10, riboflavin, and alpha lipoic acid are equivocal, these substances may also be considered in patients who express an interest in alternative treatments.


Migraine Attack Migraine With Aura Cortical Spreading Depression Magnesium Deficiency Herbal Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Altura BT, Altura BM (1982) The role of magnesium in etiology of strokes and cerebrovasospasm. Magnesium 1:277–291Google Scholar
  2. Altura BT, Altura BM (1989) Withdrawal of magnesium causes vasospasm while elevated magnesium produced relaxation of tone in cerebral arteries. Neurosci Lett 20:323–327CrossRefGoogle Scholar
  3. Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio A (1987) Mg2+- Ca2+ interaction in contractility of vascular smooth muscle: Mg2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 65:729–745PubMedCrossRefGoogle Scholar
  4. Altura BT, Shirley T, Young CC, Dell'Ofrano K, Handwerker SM, Altura BM (1992) A new method for the rapid determination of ionized Mg2+ in whole blood, serum and plasma. Meth Find Exp Clin Pharmacol 14:297–304Google Scholar
  5. Altura BT, Shirley TL, Young CC, Dell'Ofrano K, Hiti J, Welsh R, Yeh Q, Barbour RL, Altura BM (1994) Characterization of a new ion selective electrode for ionized magnesium in whole blood, plasma, serum and aqueous samples. Scand J Clin Lab Invest Suppl 54(217):21–36CrossRefGoogle Scholar
  6. Barbiroli B, Montagna P, Cortelli P et al (1992) Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 42:1209–1214PubMedGoogle Scholar
  7. Baudouin-Legros M, Dard B, Guichency P (1986) Hyperreactivity of platelets from spontaneously hypertensive rats role of external magnesium. Hypertension 8:694–699PubMedGoogle Scholar
  8. Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL (1993) Treatment of complex I deficiency with riboflavin. J Neurol Sci 118:181–187PubMedCrossRefGoogle Scholar
  9. Bianchi A, Salomone S, Caraci F et al (2004) Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm 69:297–312PubMedCrossRefGoogle Scholar
  10. Bigal ME, Bordini Ca, Tepper SJ, Speciali JG (2002) Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 22:345–353PubMedCrossRefGoogle Scholar
  11. Boehnke C, Reuter U, Flach U et al (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis- an open study in a tertiary care centre. Eur J Neurol 11:475–477PubMedCrossRefGoogle Scholar
  12. Bresolin N, Martinelli P, Barbiroli B et al (1991) Muscle mitochondrial DNA deletion and 31P-NMR spectroscopy alterations in a migraine patient. J Neurol 104:182–189Google Scholar
  13. Bryn W, Coran MH, Schultz PG, Rimbach G, Krucker T (2004) Age-related effect of ginkgo biloba on synaptic plasticity and excitability. Neurobiol Aging 25:955–962CrossRefGoogle Scholar
  14. Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C (2005) A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia 25:199–204PubMedCrossRefGoogle Scholar
  15. Coan EJ, Collingridge GL (1985) Magnesium ions block an N-methyl D-aspartate receptor-mediated component of synaptic transmission in rat hippocampus. Neurosci Lett 53:21–26PubMedCrossRefGoogle Scholar
  16. Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ (2001) Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 38:621–627PubMedCrossRefGoogle Scholar
  17. D’Andrea G, Bussone G, Allais G et al (2009) Efficacy of ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci 30(Suppl 1):S121–S124PubMedCrossRefGoogle Scholar
  18. De Bree A, Verschuren WM, Kromhout D et al (2002) Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 54:599–618PubMedCrossRefGoogle Scholar
  19. De Weerdt CJ, Bootsma HPR, Hendricks H (1996) Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of feverfew preparation. Phytomedicine 3:225–230Google Scholar
  20. Demirkaya S, Vural O, Dora B, Topcuoglu MA (2001) Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41:171–177PubMedCrossRefGoogle Scholar
  21. Di Rosa G, Attina S, Spano M et al (2007) Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms. Headache 47:1342–1344PubMedCrossRefGoogle Scholar
  22. Diener HC, Rahlfs VW, Danesch U (2004) The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 51:89–97PubMedCrossRefGoogle Scholar
  23. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH (2005) Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention- a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 25(11):1031–1041PubMedCrossRefGoogle Scholar
  24. DiLorenzo C, Pierelli F, Coppola G et al (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72:1588–1594CrossRefGoogle Scholar
  25. Draves AH, Walker SE (2003) Parthenolide content of Canadian commercial feverfew preparations: label claims are misleading in most cases. Can Pharm J RPC 136:23–30Google Scholar
  26. Droy-Lefaix MT, Doly M (1992) EGb 761, a retinal free-radical scavenger. In: Christen Y, Constantin J, Lacour M (eds) Effect of ginkgo biloba extract (EGb 761) and central nervous system. Elsevier, ParisGoogle Scholar
  27. Eaton J (1998) Butterbur, herbal help for migraine. Nat Pharm 2:23–24Google Scholar
  28. Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB (2001) Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135:344–351PubMedGoogle Scholar
  29. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G (1991) Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 31:298–301PubMedCrossRefGoogle Scholar
  30. Gallai V, Sarchielli P, Costa G et al (1992) Serium and salivary magnesium levels in migraine results in a group of juvenile patients. Headache 32:132–135PubMedCrossRefGoogle Scholar
  31. Gallai V, Sarchielli P, Morucci P, Abbritti G (1993) Red blood cell magnesium levels in migraine patients. Cephalalgia 13:94–98PubMedCrossRefGoogle Scholar
  32. Gallai V, Sarchielli P, Morucci P, Abbritti G (1994) Magnesium content of monomuclear blood cells in migraine patients. Headache 34:160PubMedCrossRefGoogle Scholar
  33. Grossman M, Schmidrams H (2000) An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 38:430–435Google Scholar
  34. Heptinstall S, White A, Williamson L, Mitchell JRA (1985) Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leukocytes. Lancet 1:1071–1074PubMedCrossRefGoogle Scholar
  35. Heptinstall S, Goenewegen WA, Spangenberg P, Loesche W (1987) Extracts of feverfew may inhibit platelet behaviour via neutralisation of suphydryl groups. J Pharm Pharmacol 39:459–465PubMedCrossRefGoogle Scholar
  36. Hershey AD, Powers SW, Vockell AB et al (2007) Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 47:73–80PubMedCrossRefGoogle Scholar
  37. Hobbs CA, Cleves MA, Melnyk S et al (2005) Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. Am J Clin Nutr 81:147–153PubMedGoogle Scholar
  38. Jain AC, Sethi NC, Balbar PK (1985) A clinical electroencephalographic and trace element study with special reference to zinc, copper and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J Neurol Suppl 232:161Google Scholar
  39. Johnson ES, Kadam NP, Hylands DM, Hylands PJ (1985) Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 291:569–573CrossRefGoogle Scholar
  40. Koo B, Becker LE, Chuang S et al (1993) Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations. Ann Neurol 34:25–32PubMedCrossRefGoogle Scholar
  41. Koseoglu E, Talashoglu A, Gonul AS, Kula M (2008) The effects of magnesium prophylaxis in migraine without aura. Magnes Res 21:101–108PubMedGoogle Scholar
  42. Kuritzky A, Elhacham Y, Yerushalmi Z, Hering R (1994) Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 44(Suppl 2):293 PGoogle Scholar
  43. Kurth T (2007) Migraine and ischaemic vascular events. Cephalalgia 27:965–975PubMedCrossRefGoogle Scholar
  44. Lanteri-Minet M, Desnuelle C (1996) Migraine and mitochondrial dysfunction. Rev Neurol 152:234–238PubMedGoogle Scholar
  45. Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L (2009) The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics 19:422–428PubMedCrossRefGoogle Scholar
  46. Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A (2004) Petsites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63:2240–2244PubMedGoogle Scholar
  47. Magis D, Ambrosini A, Sandor P et al (2007) A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 47:52–57PubMedCrossRefGoogle Scholar
  48. Majamaa K, Turkka J, Karppa M, Winqvist S, Hassinen IE (1997) The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct. Neurology 49:1331–1334PubMedGoogle Scholar
  49. Makheja AM, Bailey JM (1982) A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med 8:653–660PubMedGoogle Scholar
  50. Matalon R, Tumpf DA, Kimberlee M et al (1984) Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. J Pediatr 104:65–69PubMedCrossRefGoogle Scholar
  51. Mauskop M, Altura BM (1998) Magnesium for migraine: rationale for use and theapeutic potential. CNS Drugs 9:185–190CrossRefGoogle Scholar
  52. Mauskop A, Altura BT, Cracco RQ, Altura BM (1993) Deficiency in serum in ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2+/IMg2+ ratio. Headache 33:135–138PubMedCrossRefGoogle Scholar
  53. Mauskop A, Altura BT, Cracco RQ et al (1995) Intravenous magnesium sulfate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci 89:633–636PubMedGoogle Scholar
  54. Mauskop A, Altura BT, Cracco RQ, Altura BM (1996) Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 36:154–160PubMedCrossRefGoogle Scholar
  55. Mauskop A, Altura BT, Altura BM (2002) Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 42:242–248PubMedCrossRefGoogle Scholar
  56. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N (1997) Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 54:362–368PubMedGoogle Scholar
  57. Mody I, Lambert JD, Heinemann U (1987) Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 57:869–888PubMedGoogle Scholar
  58. Montagna P, Cortell P, Barbiroli B (1994a) Magnetic resonance spectroscopy studies in migraine. Cephalalgia 14:184–193PubMedCrossRefGoogle Scholar
  59. Montagna P, Cortelli P, Monari L et al (1994b) 31P magnetic resonance spectroscopy in migraine without aura. Neurology 44:666–669PubMedGoogle Scholar
  60. Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16:157–168PubMedCrossRefGoogle Scholar
  61. Murphy JJ, Heptinstall S, Mitchell JR (1988) Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2:189–192PubMedCrossRefGoogle Scholar
  62. Nogami K, Hirashima Y, Endo S, Takaku A (1997) Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures. Brain Res 754:72–78PubMedCrossRefGoogle Scholar
  63. Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, Bender S, Hermanns U, Resch F (2008) Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain 12:301–313PubMedCrossRefGoogle Scholar
  64. Ojaimi J, Katsabanis S, Bower S et al (1998) Mitochondrial DNA in stroke and migraine with aura. Cerebrovasc Dis 8:102–106PubMedCrossRefGoogle Scholar
  65. Palevitch D, Earon G, Carasso R (1997) Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a placebo-controlled doulbe-blind study. Phytother Res 11:508–511CrossRefGoogle Scholar
  66. Pearlman EM, Fisher S (2001) Preventive treatment for childhood and adolescent headache: role of once-daily montelukast sodium. Cephalalgia 21:461CrossRefGoogle Scholar
  67. Peikert A, Wilimzig C, Kohne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16:257–263PubMedCrossRefGoogle Scholar
  68. Penn AMW, Lee JWK, Thuillier P et al (1992) MELAS syndrome with mitochondrial tRNALeu (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 42:2147–2152PubMedGoogle Scholar
  69. Pfaffenrath V, Wessely P, Meyer C et al (1996) Magnesium in the prophylaxis of migraine-A double-blind, placebo-controlled study. Cephalalgia 16:436–440PubMedCrossRefGoogle Scholar
  70. Pfaffenrath V, Diener HC, Fisher M, Friede M, Henneicke-von Zepelin HH (2002) The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis- a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 22:523–532PubMedCrossRefGoogle Scholar
  71. Pittler MH, Ernst E (2004) Feverfew for preventing migraine. Cochrane Database Syst Rev 1:CD002286PubMedGoogle Scholar
  72. Pothmann R, Danesch U (2005) Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 45:196–203PubMedCrossRefGoogle Scholar
  73. Pugh WH, Sambo K (1988) Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 40:743–745PubMedCrossRefGoogle Scholar
  74. Ramadan NM, Halvorson H, Vande-Linde A et al (1989) Low brain magnesium in migraine. Headache 29:590–593PubMedCrossRefGoogle Scholar
  75. Rossi P, Di Lorenzo G, Malpezzi MG et al (2005) Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia 25:493–506PubMedCrossRefGoogle Scholar
  76. Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Schechter AL, Silberstein SD (2002) Open label trial of Coenzyme Q10 as a migraine preventive. Cephalalgia 22:137–141PubMedCrossRefGoogle Scholar
  77. Rubino E, Ferrero M, Rainero I et al (2009) Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia 29:818–825PubMedCrossRefGoogle Scholar
  78. Sandor PS, DiClemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64:713–715PubMedCrossRefGoogle Scholar
  79. Sarchielli P, Coata G, Firenze C, Morucci P, Abbritti G, Gallai V (1992) Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients. Cephalalgia 12:21–27, 42PubMedCrossRefGoogle Scholar
  80. Scher AI, Terwindt GM, Verschuren WMM et al (2006) Migraine and MTHFRC677T genotype in a population-based sample. Ann Neurol 59:372–375PubMedCrossRefGoogle Scholar
  81. Schoenen J, Sianard-Gainko J, Lenaerts M (1991) Blood magnesium levels in migraine. Cephalalgia 11:97–99PubMedCrossRefGoogle Scholar
  82. Schoenen J, Jacquy J, Lanaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 50:466–470PubMedGoogle Scholar
  83. Sheftell F, Rapoport A, Weeks R, Walker B, Gammerman I, Baskin S (2000) Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 40:158–163PubMedCrossRefGoogle Scholar
  84. Smeets MC, Vernooy CB, Souverjin JHM, Ferrari MD (1994) Intracellular and plasma magnesium in familial hemiplegic migraine and migraine with and without aura. Cephalalgia 14:29–32PubMedCrossRefGoogle Scholar
  85. Soriani S, Arnaldi C, De Carlo L et al (1995) Serum and red blood cell magnesium levels in juvenile migraine patients. Headache 35:14–16PubMedCrossRefGoogle Scholar
  86. Thomas J, Thomas E, Tomb E (1992) Serum and erythrocyte magnesium concentrations and migraine. Magnes Res 5:127–130PubMedGoogle Scholar
  87. Thomas J, Millot JM, Sebille S, Delabroise AM et al (2000) Free and total magnesium in lymphocytes of migraine patients- effect of magnesium-rich mineral water intake. Clin Chim Acta 295:64–75CrossRefGoogle Scholar
  88. Trauninger A, Pfund Z, Koszegi T, Czopf J (2002) Oral magnesium load test in patients with migraine. Headache 42:114–119PubMedCrossRefGoogle Scholar
  89. Turlapaty PDMV, Altura BM (1980) Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 208:198–200PubMedCrossRefGoogle Scholar
  90. Tzourio C, Iglesias S, Hubert JB et al (1993) Migraine and risk of ischaemic stroke: a case-control study. BMJ 307:289–292PubMedCrossRefGoogle Scholar
  91. Vogler BK, Pittler BK, Ernst E (1998) Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 18:704–708PubMedCrossRefGoogle Scholar
  92. Wang X, Qin X, Demirtas H et al (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369:1876–1882PubMedCrossRefGoogle Scholar
  93. Weglicki WB, Phillips TM (1992) Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 263(pt 2):R734–R737PubMedGoogle Scholar
  94. Welch KM, Levine SR, D’Andrea G, Schultz LR, Helpern JA (1989) Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39:538–541PubMedGoogle Scholar
  95. Willigmann I, Freudenstein J (1998) Production of a stable feverfew (Tanadetum parthenium) extract as an active substance for a pharmaceutical product. In: Poster symposium. Society for Medicinal Plant Research, ViennaGoogle Scholar

Copyright information

© Lifting The Burden 2011

Authors and Affiliations

  1. 1.New York Headache CenterNew YorkUSA
  2. 2.Department of Clinical NeurosciencesCentre for Clinical Neurosciences and Neurological Research, St Vincent’s HospitalMelbourneAustralia

Personalised recommendations